EUCTR2017-000920-81-DE进行中（未招募）1 期
A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON). - POSEIDO
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Aged at least 18 years.
- •2. Histologically or cytologically documented Stage IV NSCLC.
- •3. Confirmed tumor PD-L1 status prior to randomization.
- •4. Patients must have tumors that lack activating EGFR mutations and ALK fusions.
- •5. No prior chemotherapy or any other systemic therapy for metastatic NSCLC.
- •6. World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- •7. No prior exposure to immune-mediated therapy, excluding therapeutic anticancer vaccines.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 590
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 590
排除标准
- •1. Mixed small-cell lung cancer and NSCLC histology, sarcomatoid variant.
- •2. Active or prior documented autoimmune or inflammatory disorders.
- •3. Brain metastases or spinal cord compression unless the patient’s condition is stable and off steroids.
- •4. Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus.
研究者
相似试验
进行中（未招募）
1 期
A Research Study to Gather Scientific Information About the Efficacy, Safety, and Tolerability of the Investigational Drug APL-2 In Treating Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH), a Disease Associated With Anemia, In A Randomly Assigned Comparison With the Current Standard of Care Treatment Approved for PNH At Multiple Research Centres.PNH is an acquired, rare, clonal, non-malignant hematologic disease characterized by complement-mediated RBC hemolysis with or without hemoglobinuria, an increased susceptibility to thrombotic episodes, and/or some degree of bone marrow dysfunction.PNH is caused by complement-mediated lysis of erythrocyte clones lacking functional CD55 and CD59 on their surface. These RBCs are particularly susceptible to the MAC and have been shown to lyse readily in the presence of complement activation.MedDRA version: 20.1Level: LLTClassification code 10055629Term: Paroxysmal nocturnal hemoglobinuriaSystem Organ Class: 100000004857EUCTR2017-004268-36-ESApellis Pharmaceuticals, Inc.80
进行中（未招募）
1 期
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy alone for Patients With Lung Cancer (POSEIDON).EUCTR2017-000920-81-HUAstraZeneca AB1,000
进行中（未招募）
1 期
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy alone for Patients With Lung Cancer (POSEIDON).First-line patients with metastatistic non-small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusionsMedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2017-000920-81-PLAstraZeneca AB1,000
进行中（未招募）
1 期
A Research Study to Gather Scientific Information About the Efficacy, Safety, and Tolerability of the Investigational Drug APL-2 In Treating Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH), a Disease Associated With Anemia, In A Randomly Assigned Comparison With the Current Standard of Care Treatment Approved for PNH At Multiple Research Centres.PNH is an acquired, rare, clonal, non-malignant hematologic disease characterized by complement-mediated RBC hemolysis with or without hemoglobinuria, an increased susceptibility to thrombotic episodes, and/or some degree of bone marrow dysfunction.PNH is caused by complement-mediated lysis of erythrocyte clones lacking functional CD55 and CD59 on their surface. These RBCs are particularly susceptible to the MAC and have been shown to lyse readily in the presence of complement activation.MedDRA version: 21.1Level: LLTClassification code 10055629Term: Paroxysmal nocturnal hemoglobinuriaSystem Organ Class: 100000004857EUCTR2017-004268-36-DEApellis Pharmaceuticals, Inc.70
已完成
3 期
POSEIDOon Small Cell Lung Cancer NSCLCJPRN-jRCT2080223617AstraZeneca